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ivotal role of elevated heart rate in the
ardiovascular continuum
We congratulate Custodis et al. for demonstrating that elevated
eart rate (HR) plays a pivotal role in the vascular pathophysio-
ogy of the cardiovascular continuum [1]. An elevated HR promotes
therosclerosis via not only sympathetic overactivation, but also by
odulating the local hemodynamic environment. An elevated HR
ncreases the exposure of the endothelium to systolic low shear
tress (SS), attenuates the diastolic SS, and increases local tensile
tress, which change the arterial structure in patients with car-
iovascular risks. Thereby, HR lowering might act speciﬁcally on
therosclerosis-prone lesions, contributing to a residual risk reduc-
ion [2]. The prognostic beneﬁt of blockers in patients with stable
oronary artery disease has been called into question [3]. These
ndings might be due in part to inadequate HR control [4], indi-
ating that the physician did not use a  blocker in a HR-guided
anner, because no optimal HR level is described in the guide-
ine documentation. The SIGNIFY study will reveal the prognostic
igniﬁcance of HR lowering for stable CAD patients [5].
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